A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

The Phase 1 GALLOP study evaluating the investigational CAR-T therapy, CB-010, for treatment of lupus nephritis has launched.

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

A new study has introduced an innovative approach to CAR-T therapy that could address some of the current challenges in ...

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

For patients with relapsed/refractory large B-cell lymphoma, access to lifesaving CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be limited by post-infusion monitoring protocols ...

Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School ...

India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...